| Date | Title | Description | |
|---|---|---|---|
| 08 Jul 2024 | Other relevant information | The Company informs about the dividends payment. | Download |
| 04 Jul 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2024 | Download |
| 24 Jun 2024 | Announcement of General Shareholders' Meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. | Download |
| 11 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program | Download |
| 07 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 31 May and 6 June 2024 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
| 13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
| 07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
| 16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
| 16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |